Ascendis Pharma Files IND For Hypoparathyroidism Candidate
Zacks Investment Research | Feb 12, 2019 09:53PM ET
Ascendis Pharma A/S (NASDAQ:ASND) announced that it has submitted an Investigational New Drug (“IND”) application with the FDA related to progress of clinical development of its pipeline candidate, TransCon PTH. The IND seeks to initiate a phase II study – PaTH Forward – to evaluate safety, tolerability and efficacy of TransCon PTH in adult patients with hypoparathyroidism (“HP”).
The company is developing the candidate as a potential replacement therapy for HP, administered once-daily.
Shares of Ascendis Pharma increased 2.4% on Feb 12 following the news. The company’s shares have gained 3.3% in the past six months against the the complete list of today’s Zacks #1 Rank stocks here .
Galectin’s loss per share estimates have narrowed from 44 cents to 38 cents for 2018 and from $1.12 to 98 cents for 2019 over the past 60 days. The company delivered positive earnings surprise in all the last four quarters, with the average beat being 18.65%. Share price of the company has risen 8.5% in the past six months.
Ascendis Pharma A/S Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.